Acerca deste libro electrónico
With over 35 new FDA-approved indications since the second edition—featuring groundbreaking advancements such as CAR-T therapy—this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management.
Key Features:
- New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.
- Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.
- Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.
- Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.
- Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.
Descubrir máis
Acerca do autor
David A. Sallman, MD, Associate Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida Morsani College of Medicine, Tampa, Florida
Ateefa Chaudhury, MD, Hematologist, New Mexico Cancer Center, Albuquerque, New Mexico
Hayder Saeed, MD, Associate member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Ling Zhang, MD, Senior Member, Professor, Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
